How to synthesize Tegoprazan?
Tegoprazan is a novel orally active P-CAB. Key challenges in the drug preparation are the construction of the tetrasubstituted aryl core and the efficient introduction of the enantiomerically pure chromanol side chain.
Dec 25,2023
What is Tegoprazan?
Tegoprazan was approved by the Ministry of Food and Drug Safety (MFDS) for marketing in July 2018 for the treatment of gastroesophageal reflux disease and erosive esophagitis. Tegoprazan was originally developed by Pfizer.
Feb 24,2020